Literature DB >> 14583036

Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.

Nora S Green1, Satheesh K Palaninathan, James C Sacchettini, Jeffery W Kelly.   

Abstract

The misfolding of transthyretin (TTR), including rate-limiting tetramer dissociation and partial monomer denaturation, is sufficient for TTR misassembly into amyloid and other abnormal quaternary structures associated with senile systemic amyloidosis, familial amyloid polyneuropathy, and familial amyloid cardiomyopathy. Monovalent small molecules that bind to one or both of the unoccupied thyroid hormone binding sites at the TTR quaternary structure interface stabilize the native state, raising the kinetic barrier for tetramer dissociation sufficiently that the rate of dissociation, and therefore amyloidosis, becomes slow. Bivalent amyloid inhibitors that bind to both binding sites simultaneously are reported herein. The candidate bivalent inhibitors are generally unable to bind to the native TTR tetramer and typically do not engage in monovalent binding owing to a strong inhibitor orientation preference. However, the TTR quaternary structure can assemble around several of the bivalent inhibitors if the inhibitor intercepts the protein before assembly occurs. Some of the wild-type TTR.bivalent inhibitor complexes prepared in this fashion retain a tetrameric structure when subjected to substantial denaturation stresses (8 M urea, 120 h). The best bivalent inhibitor reduced acid-mediated TTR (3.6 microM) amyloid fibril formation to 6% of that exhibited by TTR in the absence of inhibitor, a significant improvement over the approximately 30% observed for the best monovalent inhibitors (3.6 microM, 72 h). The apparent dissociation rate of the best bivalent inhibitor is effectively zero, consistent with the idea that TTR tetramer dissociation and inhibitor dissociation are linked-as a result of the inhibitor-templating tetramer assembly. X-ray cocrystal structures of two of the complexes demonstrate that the bivalent inhibitors simultaneously occupy both sites in TTR, consistent with the 1:1 binding stoichiometry derived from HPLC analysis. The purpose of this study was to demonstrate that bivalent inhibitors could be useful; what resulted are the best inhibitors produced to date. In this context, molecules capable of intercepting TTR during folding and assembly in the lumen of the endoplasmic reticulum would be of obvious interest.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14583036     DOI: 10.1021/ja030294z

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  29 in total

1.  A stilbene that binds selectively to transthyretin in cells and remains dark until it undergoes a chemoselective reaction to create a bright blue fluorescent conjugate.

Authors:  Sungwook Choi; Derrick Sek Tong Ong; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2010-10-21       Impact factor: 15.419

2.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.

Authors:  Christine E Bulawa; Stephen Connelly; Michael Devit; Lan Wang; Charlotte Weigel; James A Fleming; Jeff Packman; Evan T Powers; R Luke Wiseman; Theodore R Foss; Ian A Wilson; Jeffery W Kelly; Richard Labaudinière
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

3.  Development of dimeric modulators for anti-apoptotic Bcl-2 proteins.

Authors:  Liangyou Wang; Fansen Kong; Candis L Kokoski; David W Andrews; Chengguo Xing
Journal:  Bioorg Med Chem Lett       Date:  2007-10-30       Impact factor: 2.823

4.  A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.

Authors:  Sungwook Choi; Natàlia Reixach; Stephen Connelly; Steven M Johnson; Ian A Wilson; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2010-02-03       Impact factor: 15.419

5.  Partitioning conformational intermediates between competing refolding and aggregation pathways: insights into transthyretin amyloid disease.

Authors:  R Luke Wiseman; Evan T Powers; Jeffery W Kelly
Journal:  Biochemistry       Date:  2005-12-20       Impact factor: 3.162

6.  A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.

Authors:  Sungwook Choi; Jeffery W Kelly
Journal:  Bioorg Med Chem       Date:  2010-12-30       Impact factor: 3.641

Review 7.  Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis.

Authors:  Susan L Lindquist; Jeffery W Kelly
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-12-01       Impact factor: 10.005

8.  Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.

Authors:  Steven M Johnson; Stephen Connelly; Ian A Wilson; Jeffery W Kelly
Journal:  J Med Chem       Date:  2008-09-24       Impact factor: 7.446

9.  Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma.

Authors:  Sungwook Choi; Stephen Connelly; Natàlia Reixach; Ian A Wilson; Jeffery W Kelly
Journal:  Nat Chem Biol       Date:  2010-02       Impact factor: 15.040

10.  Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors.

Authors:  Teresa Mairal; Joan Nieto; Marta Pinto; Maria Rosário Almeida; Luis Gales; Alfredo Ballesteros; José Barluenga; Juan J Pérez; Jesús T Vázquez; Nuria B Centeno; Maria Joao Saraiva; Ana M Damas; Antoni Planas; Gemma Arsequell; Gregorio Valencia
Journal:  PLoS One       Date:  2009-01-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.